This is the story of a GSK vaccine once morest shingles. Its worldwide production is carried out in Saint-Amand-les-Eaux, in the North. Authorized since 2018, it is available throughout the European Union… except in France. Due to difficulties in accessing the market, says one at GSK. This is the adventure of Zolgensma, a gene therapy that can treat babies with a rare neuromuscular genetic disease, often fatal before the age of 2 years. Designed by Genethon, thanks to donations from Telethon, this biomedicine was licensed to Avexis, the American biotech which developed it with huge funding, before being acquired by the giant Novartis. Which charges the single dose at around 2 million euros… This is the experience, made by all, of stock shortages and supply tensions for basic drugs such as paracetamol and amoxicillin, this winter, so that France was facing a triple epidemic of Covid-19, influenza and bronchiolitis.
[…]
This article is reserved for our L’Usine Nouvelle subscribers
Support expert journalism.
Login
VOS INDICES
source
Selected for you
